Cocrystal(US:COCP)2020-04-24 15:03Collaboration and Financials - Cocrystal recognized revenue of $6560000 in 2019 from the Merck collaboration and is eligible for up to $156 million in milestone payments and royalties[8] - As of January 31, 2020, Cocrystal had 52100000 common shares outstanding[59] - As of January 31, 2020, Cocrystal's fully diluted shares outstanding were 53307139[58] - As of December 31, 2019, Cocrystal had a cash balance of approximately $7400000[59] Hepatitis C (HCV) Program - In a Phase 2a study, 67% of subjects (8 out of 12) achieved both SVR12 and SVR24, considered a virologic cure, with a 6-week treatment regimen[29] - CC-31244 demonstrated a viral load decline of 3 logs by 48 hours in HCV GT1 subjects during Phase 1b data[22] - Approximately 71 million people are infected with Hepatitis C globally[15] - Only 2% of infected Hepatitis C patients are being treated[17] Influenza Program - The global influenza market was valued at nearly $5600000000 in 2017 and is expected to reach nearly $6500000000 by 2022[34] - Influenza causes 1 billion cases annually[34] - Influenza results in up to 650000 deaths worldwide annually[35] Coronavirus (COVID-19) Program - Cocrystal expects to initiate preclinical studies of COVID-19 inhibitors in H2 2020[11] - Cocrystal acquired exclusive patent rights and know-how for coronavirus therapeutics for human use from Kansas State University Research Foundation (KSURF)[9]